It is used for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm who cannot take beta blockers. It is also being used off-label in the treatment of inappropriate sinus tachycardia.Ivabradine stands as a pharmacological option for controlling HR and rhythm without associated side effects in postoperative CABG patients with IST Chest pain It may be as effective as the beta blocker atenolol and comparable with amlodipine in the management of chronic stable angina. Heart failure It is used in combination with beta blockers in people with heart failure with LVEF lower than 35 percent inadequately controlled by beta blockers alone and whose heart rate exceeds 70 beats per minute. In people not sufficiently managed with beta blockers for their heart failure adding<unk>  decreases the risk of hospitalization for heart failure. Tachycardia The clinical use of<unk>  is predicated on its mechanism of action on sinoatrial nodal tissue where it selectively inhibits the funny current (If) and results in a decrease in heart rate.<unk> ’s most frequent application in electrophysiology is for the treatment of inappropriate sinus tachycardia. Its use for inappropriate sinus tachycardia is not a European Medicines Agency/Food and Drug Administration–approved indication for<unk> . It has been used experimentally for the treatment of postural orthostatic tachycardia syndrome in patients with long COVID.
Ivabradine
Lofexidine
Setiptiline
Maprotiline
Verapamil
Nortilidine
Veratridine
Procainamide